01

No tubes. No wires.

Non-invasively monitors patient’s breathing, gives reliable alerts for deteriorating volumes, apnea and obstructive breathing

02

Cost-effective

Monitors breathing at a fraction of the cost of existing monitoring technologies by utilizing off-the-shelf hardware.

03

Intuitive & Simple

Straight-forward to use and interpret by all medical staff. Output consists of standard respiratory parameters.

MEET BREATHEVISION

OUR STORY

BreatheVision was founded in 2013 on the need to develop a simple method for early detection of breathing deterioration in patients under conscious sedation... The founders built on their expertise in machine vision and missile navigation algorithms to invent a way to quantify breathing through analyzing chest micro-movements based on low-cost off the shelf hardware.

OUR VISION

To improve patient safety by monitoring essential breathing parameters through machine learning technology and providing immediate warning.

OUR PRODUCT

Our first product, the SafeSed monitoring system, was developed for medical staff to continuously monitor respiration for post anesthesia sedated patients.

PROSPECTIVE TARGET MARKETS

COVID-19 respiratory monitoring

Post-anesthesia

monitoring

Procedural

sedation

Remote and home monitoring

Neonatal

hospital

monitoring

CLINICAL VALIDATION

BreatheVision performed clinical validation of the SafeSed monitoring system at Meir Medical Center (Kfar Saba, Israel) and Tel-Aviv Medical Center.

The SafeSed system was compared to conventional means of respiratory monitoring:

• Colonoscopy - SafeSed vs. Capnography

• Operation Room - SafeSed vs. Anesthesia Machine

• Healthy Volunteers - SafeSed vs. Spirometry

• PACU post anesthesia - SafeSed vs. Pulse Oximetry and Clinical Logs​

SafeSed signal vs. Capnograph signal

OUR TEAM

Menashe Terem
CEO

Ditza Aurebach
Founder

Ofer Leizerovich
 

Omri Cohen
Project Manager

Ziv Geva
CTO

Omri Tzur

Clinical Project Manager

Avi Kriheli

Program Manager

Ofer Orgal

Menashe Terem, MA

CEO & Co-Founder

Former executive at El-Al Airlines who also led several medical device companies into OTC and professional markets worldwide.

Ditza Auerbach, PhD

Founder

Physicist experienced in leading imaging and machine learning R&D at Aspect Imaging and Applied Materials. 

Ziv Geva

CTO

Prof. Ilan Shimshoni

Scientific Advisor

Professor of Information Systems at the Computer Science Department at Technion, University of Haifa (Israel)

MEDICAL NEED

Adverse events associated with sedation

“Drug-induced respiratory depression is the primary cause of morbidity associated with sedation and analgesia”

American Society of Gastroenterology Nurses and Associates 2016

"…hospitals are expected to address monitoring for …respiratory

depression related to opioids for post-operative patients…. monitoring of ventilation may warrant … to assess breathing"

Centers for Medicare & Medicaid Services (CMS), 2014 

Current monitoring methods

“Staff should … not to rely on pulse oximetry alone because pulse oximetry can suggest adequate oxygen saturation in patients … experiencing respiratory depression, especially when supplemental oxygen is being used.”

The Joint Commission Sentinel Event Alert, 2012

“Capnography devices often indicate problems where none exist… At worst, frequent alarm errors may lead to alarm fatigue and a tendency to ignore valid alarms.”

American Society for Gastrointestinal Endoscopy, 2012

“No studies have been published on the effectiveness of capnography on clinically important outcomes (rescue team activation, ICU transfers, or mortality). Etco2 may not accurately reflect the Paco2 in nonintubated patients in the setting of low-tidal volume breathing or mouth breathing... Capnography may require extra training of staff members before implementation.”

Anesthesia & Analgesia; Vol. 125 Issue 6, 2017

Future monitoring methods

“Quantitative monitoring of the volume of expired gas is strongly encouraged.”

American Society of Anesthesiologists, 2015

SafeSed has been developed for medical staff, to continuously monitor respiration.

OUR

TECHNOLOGY

SafeSed recognizes deterioration in patient's breathing that requires immediate medical attention.

Apnea

Obstructive

Shallow

SafeSed - No Tubes, No Wires

Simply Brilliant!​

NEWS

1st clinical trial for SafeSed in the Gastro clinic began recruiting at Meir Medical Centre, Israel.

DEC.

2016

DEC.

2nd US Patent granted for the SafeSed system. 

​

2019

1st US Patent granted for the SafeSed system. 

OCT.

2017

Completed development of a Central Monitoring System for remote monitoring of multiple COVID-19 patients simultaneously.

JUN.

2020

Successful FDA Pre-Submission meeting for the SafeSed device.

APR.

2018

FEB.

Healthy Volunteers Clinical Trial for performance and accuracy evaluation of SafeSed at Meir Medical Centre, Israel has been completed successfully.

2020

Clinical Validation Trial for Volume determination by SafeSed vs. Anesthesia machine at Meir Medical Centre, Israel has completed successfully.

AUG.

2018

APR.

4th Grant from the Israel Innovation Authority for COVID-19 Pilot.

2020

First round of crowd-funding completed. Second round during Q1 2020. Total of 4.5M NIS raised.

AUG.

2019

OCT.

2020

Pilot in PACU for respiratory deterioration monitoring and prediction by SafeSed began recruiting at Tel-Aviv Medical Centre, Israel.